Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBI-001 Gel for Atopic Dermatitis
NCT04192513Phase 2Terminated
- Sponsor
- DermBiont, Inc.
- Start
- May 2019
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in atopic dermatitis (AD) (3 cohorts), sponsored by DermBiont, Inc. Primary endpoint: Change in Local Tolerability Based on Scale Listed at Day 14. Started May 2019; status: terminated.
02
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04192513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192513.